NovoCure

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. 

CEO
Frank Leonard
CEOFrank Leonard
Employees
1,488
Employees1,488
Headquarters
St. Helier, Jersey
HeadquartersSt. Helier, Jersey
Founded
2000
Founded2000
Employees
1,488
Employees1,488

NVCR Key Statistics

Market cap
1.53B
Market cap1.53B
Price-Earnings ratio
-8.46
Price-Earnings ratio-8.46
Dividend yield
Dividend yield
Average volume
1.25M
Average volume1.25M
High today
$14.07
High today$14.07
Low today
$13.50
Low today$13.50
Open price
$13.75
Open price$13.75
Volume
792.01K
Volume792.01K
52 Week high
$27.47
52 Week high$27.47
52 Week low
$10.70
52 Week low$10.70

Stock Snapshot

The current NovoCure(NVCR) stock price is $13.69, with a market capitalization of 1.53B. The stock trades at a price-to-earnings (P/E) ratio of -8.46.

As of 2026-01-18, NovoCure(NVCR) stock has fluctuated between $13.50 and $14.07. The current price stands at $13.69, placing the stock +1.4% above today's low and -2.7% off the high.

The NovoCure(NVCR)'s current trading volume is 792.01K, compared to an average daily volume of 1.25M.

In the last year, NovoCure(NVCR) shares hit a 52-week high of $27.47 and a 52-week low of $10.70.

In the last year, NovoCure(NVCR) shares hit a 52-week high of $27.47 and a 52-week low of $10.70.

NVCR News

Simply Wall St 4d
A Look At NovoCure Valuation After Record 2025 Revenue And CEO Transition

NovoCure (NVCR) has drawn fresh attention after reporting record 2025 revenues of $655 million, appointing Frank Leonard as CEO, and advancing FDA submissions f...

A Look At NovoCure Valuation After Record 2025 Revenue And CEO Transition
Simply Wall St 5d
Is NovoCure A Rare Opportunity After A 45.9% One Year Share Price Fall

If you are trying to figure out whether NovoCure at around US$14.18 is a potential bargain or a value trap, you are in the right place. The share price has bee...

Is NovoCure A Rare Opportunity After A 45.9% One Year Share Price Fall
TipRanks 7d
Novocure reports preliminary Q4 revenue $174.4M, consensus $168.93M

Reports Preliminary FY25 revenue $655.4M, consensus $651.21M. “Novocure (NVCR) exits 2025 having achieved record annual revenue, providing the financial strengt...

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .